XML 86 R53.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Entities and Acquisitions - Entasis Therapeutics Holdings, Inc. (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 5 Months Ended 12 Months Ended
Feb. 17, 2022
USD ($)
$ / shares
Feb. 28, 2023
USD ($)
Mar. 31, 2022
USD ($)
Jul. 11, 2022
USD ($)
Dec. 31, 2024
USD ($)
Director
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Subsidiary or Equity Method Investee [Line Items]              
Total debt         $ 453,500 $ 453,500  
Net loss attributable to noncontrolling interests         $ 0 $ 0 $ 6,341
Entasis Therapeutics Holdings Inc              
Subsidiary or Equity Method Investee [Line Items]              
Number of investee's board members which may be designated by the Company | Director         2    
Remeasurement loss     $ 7,800        
Payment towards convertible promissory note       $ 0      
Measurement period adjustments for change in value of goodwill   $ 1,200         (4,700)
Measurement period adjustments for change in estimated purchase price             (1,400)
Measurement period adjustments for change in value of noncontrolling interests             1,700
Measurement period adjustments for change in value of intangible assets   (800)         2,500
Measurement period adjustments increase decrease in deferred tax liabilities   $ 400          
Noncontrolling interests $ 38,500            
Net loss attributable to noncontrolling interests             $ (13,600)
Entasis Therapeutics Holdings Inc | Consolidated Investees              
Subsidiary or Equity Method Investee [Line Items]              
Equity method investment ownership percentage 59.90%            
Entasis Therapeutics Holdings Inc | Securities purchase agreement | Convertable promissory note              
Subsidiary or Equity Method Investee [Line Items]              
Total debt $ 15,000            
Debt Instrument, annual interest rate 0.59%            
Debt instrument maturity date Aug. 18, 2022            
Conversion price (dollars per share) | $ / shares $ 1.48            
Entasis Therapeutics Holdings Inc | Common stock              
Subsidiary or Equity Method Investee [Line Items]              
Fair value of equity securities $ 64,500            
Entasis Therapeutics Holdings Inc | Warrants              
Subsidiary or Equity Method Investee [Line Items]              
Fair value of equity securities $ 31,400